StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Candel Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Candel Therapeutics's price to sales ratio was 298.4× on Apr 28, 2023.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 2023298.4×−118.6
2022Dec 30, 2022417.1×–

More Candel Therapeutics figures

See a number that looks wrong?